Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).

We have developed two parallel series, A and B, of CX3CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]pyrimidine core structure, we were able to achieve compounds with high selectivity for CX3CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with α-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX3CR1 antagonists.

[1]  P. Prusis,et al.  Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  John J. M. Wiener,et al.  Recent advances in the design of cathepsin S inhibitors. , 2010, Current topics in medicinal chemistry.

[3]  Dongmei Wang,et al.  Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice. , 2010, Journal of medicinal chemistry.

[4]  Kuang-Yu Liu,et al.  Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets , 2009, BMC Genomics.

[5]  N. Hewitt,et al.  Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[7]  R. Leurs,et al.  Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  L. Di,et al.  In vitro solubility assays in drug discovery. , 2008, Current drug metabolism.

[9]  Brian A. Chauder,et al.  Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. , 2008, Journal of medicinal chemistry.

[10]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[11]  M. Kikuyama,et al.  Adsorptive Depletion of Elevated Proinflammatory CD14+CD16+DR++ Monocytes in Patients With Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[12]  E. Novellino,et al.  Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. , 2008, Journal of medicinal chemistry.

[13]  R. Austin,et al.  Evaluation of a series of bicyclic CXCR2 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[14]  D. Busch,et al.  Chemokine Fractalkine Mediates Leukocyte Recruitment to Inflammatory Endothelial Cells in Flowing Whole Blood: A Critical Role for P-Selectin Expressed on Activated Platelets , 2007, Circulation.

[15]  T. Bueters,et al.  Combined approach for high-throughput preparation and analysis of plasma samples from exposure studies. , 2007, Rapid communications in mass spectrometry : RCM.

[16]  R. Austin,et al.  SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. , 2007, Bioorganic & medicinal chemistry letters.

[17]  R. Ransohoff,et al.  Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.

[18]  L. Ziegler‐Heitbrock,et al.  The CD14+ CD16+ blood monocytes: their role in infection and inflammation , 2007, Journal of leukocyte biology.

[19]  Andrea Rosario Beccari,et al.  ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. , 2006, Pharmacology & therapeutics.

[20]  F. Tacke,et al.  Migratory fate and differentiation of blood monocyte subsets. , 2006, Immunobiology.

[21]  John Unitt,et al.  Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[22]  B. Isaac,et al.  Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine)1 , 2005, The Journal of Immunology.

[23]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[24]  Bryan Roberts,et al.  Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[25]  F. Fahrenholz,et al.  The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. , 2003, Blood.

[26]  W. Metz,et al.  Unraveling the chemistry of chemokine receptor ligands. , 2003, Chemical reviews.

[27]  Ismael Zamora,et al.  pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.

[28]  Richard J. Miller,et al.  Chemokine receptors: signposts to brain development and disease , 2003, Nature Reviews Neuroscience.

[29]  R. Horuk,et al.  Chemokines, chemokine receptors and small-molecule antagonists: recent developments. , 2002, Trends in pharmacological sciences.

[30]  T. Kaufman,et al.  A simple protocol for the one pot synthesis of chiral secondary benzylic alcohols by catalytic enantioselective reduction of aromatic ketones , 2002 .

[31]  O. Yoshie,et al.  Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes That Are Defined by CX3CR1 Expression , 2002, The Journal of Immunology.

[32]  A. Proudfoot.  Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[33]  I. Forbes,et al.  CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. , 2000, Bioorganic & Medicinal Chemistry Letters.

[34]  I. Charo,et al.  Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction , 1999, The Journal of Biological Chemistry.

[35]  R. Maki,et al.  Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. , 1999, TIPS - Trends in Pharmacological Sciences.

[36]  T M Handel,et al.  Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. , 1999, Biochemistry.

[37]  W. Streit,et al.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Corey,et al.  Reduction of Carbonyl Compounds with Chiral Oxazaborolidine Catalysts: A New Paradigm for Enantioselective Catalysis and a Powerful New Synthetic Method. , 1998, Angewandte Chemie.

[39]  G. Fingerle-Rowson,et al.  Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy , 1998, Clinical and experimental immunology.

[40]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[41]  J. Gutiérrez-Ramos,et al.  Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation , 1997, Nature.

[42]  T. Shioiri,et al.  A Practical Method for Asymmetric Borane Reduction of Prochiral Ketones Using Chiral Amino Alcohols and Trimethyl Borate , 1997 .

[43]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[44]  R. Eddy,et al.  The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues. , 1995, Gene.

[45]  C. Harrington,et al.  Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. , 1990, Analytical biochemistry.

[46]  P. Ramachandran,et al.  Chiral synthesis via organoboranes. 14. Selective reductions. 41. Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent , 1988 .

[47]  O. Miyashita,et al.  Synthesis and coronary vasodilating activity of 2-substituted adenosines. , 1975, Chemical & pharmaceutical bulletin.